Onkologie. 2026:20(1):27-32 | DOI: 10.36290/xon.2026.005
New hope for patients with metastatic NSCLC and EGFR mutation
- Pneumologická klinika, 1. LF UK a Fakultní Thomayerova nemocnice, Praha
In recent years, the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutation has evolved significantly. It is no longer limited to monotherapy with tyrosine kinase inhibitors (TKIs); increasingly, more complex regimens are being used, offering greater clinical benefit to patients. One such approach is the FLAURA2 regimen, which combines osimertinib with chemotherapy and has been shown to significantly improve survival compared to osimertinib alone. The practical impact of this strategy is illustrated by our case report. In a patient with an EGFR mutation and central nervous system metastases, rapid regression of brain metastases and long-term disease control were achieved, all with good treatment tolerability.
Keywords: NSCLC, EGFR mutation, FLAURA2, osimertinib, chemotherapy, brain metastases.
Accepted: March 2, 2026; Published: March 16, 2026 Show citation
References
- Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935-1948.
Go to original source... 
Go to PubMed... - Jänne PA, Planchard D, Kobayashi K, et al. Armenteros-Monterroso E, Rukazenkov Y, Lee CK; FLAURA2 Investigators. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2026;394(1):27-38. Go to original source... Go to PubMed...
- Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open. 2021;6(5):100271. Go to original source... Go to PubMed...
- Jänne PA, Planchard D, Kobayashi K, et al. Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2024;42(7): 808-820. Go to original source... Go to PubMed...